Related Experiment Videos
Combination therapy with purine nucleoside analogs.
1Department of Hematology/Oncology, Tufts New England Medical Center, Boston, Massachusetts, USA.
Oncology (Williston Park, N.Y.)
|July 11, 2000
Summary
Pentostatin combinations show promise in treating lymphomas and leukemias. A new study explores pentostatin with cordycepin for acute lymphocytic leukemia, building on prior research in other blood cancers.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Pentostatin is effective for low-grade B- and T-cell lymphomas.
- Limited clinical data exists for pentostatin combination therapies.
- Previous combinations with alkylating agents caused significant immunosuppression.
Purpose of the Study:
- To evaluate alternating pentostatin and interferon-alfa-2a in cutaneous T-cell lymphoma.
- To assess pentostatin combinations with alkylating agents in chronic lymphocytic leukemia.
- To investigate the synergy of pentostatin and cordycepin in acute lymphocytic leukemia.
Main Methods:
- Alternating administration of pentostatin and high-dose interferon-alfa-2a.
- Combination therapy with pentostatin and alkylating agents (chlorambucil, cyclophosphamide).
- Clinical trial of pentostatin and cordycepin in acute lymphocytic leukemia.
Main Results:
- A 41% response rate with tolerable toxicity for pentostatin and interferon-alfa-2a.
- Significant immunosuppression and dose modifications required for pentostatin and alkylating agent combinations.
- In vitro data shows significant synergy between pentostatin and cordycepin.
Conclusions:
- Pentostatin combination therapies require careful management due to potential toxicities.
- Pentostatin and cordycepin combination shows potential for treating acute lymphocytic leukemia.